key: cord-0956163-o6jp2bs2
authors: Fu, Linghua; Liu, Xiao; Su, Yuhao; Ma, Jianyong; Hong, Kui
title: Prevalence and impact of cardiac injury on COVID‐19: A systematic review and meta‐analysis
date: 2020-12-31
journal: Clin Cardiol
DOI: 10.1002/clc.23540
sha: f913e9a00e4c9db2d3d7ad4d90dc6b6a9cb16e78
doc_id: 956163
cord_uid: o6jp2bs2

BACKGROUND: The exact prevalence and impact of cardiac injury in hospitalized patients with coronavirus disease 2019 (COVID‐19) is still controversial. Hence, we aim to investigate prevalence of cardiac injury and its impact on the outcomes in patients with COVID‐19. HYPOTHESIS: Cardiac injury is common and associated with higher risk of death. METHODS: We searched the Cochrane Library, PubMed, MedRxiv, and EMBASE databases from December 2019 to July 15, 2020 for studies that evaluated the prevalence and impact of cardiac injury on COVID‐19. This study has been registered with PROSPERO (International prospective register of systematic reviews)‐registration number‐CRD‐42020186120. RESULTS: Twenty‐one studies including 6297 participants were identified. The proportions of cardiac injury were 22%, 28% among hospitalized patients with COVID‐19 or severe COVID‐19 patients, respectively. The incidences of cardiac injury in advance age (>60 years) (30%) was about two‐fold than young patients (<60 years) (15%) with COVID‐19. Severe cases (42%) have seven‐fold prevalence cardiac injury than in their non‐ severe counterparts (6%). Furthermore, cardiac injury is associated with an increased risk of all‐cause mortality in patients with COVID‐19 (OR 10.11, 95% CI 4.49–22.77). In patients with severe COVID‐19, cardiac injury is associated with an increased risk of all‐cause mortality (OR: 16.79, 95% CI: 5.52–51.02). CONCLUSIONS: This was the first meta‐analysis exploring the prevalence and impact of cardiac injury on COVID‐19. Cardiac injury is common in hospitalized patients and advanced age and severe COVID‐19 patients prone to experience more risk of cardiac injury. Furthermore, cardiac injury is associated with increased risk of all‐cause mortality.

Coronavirus disease 2019 pandemic is an ongoing global public health emergency, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of July 11, 2020, there are 12 322 395 confirmed cases with 556 335 deaths reported in 216 countries. 1 COVID-19 is associated with an increased risk of acute respiratory distress syndrome and has adverse effects on other organ systems, including the heart, kidney, and liver. 2 Cardiovascular disease is a common comorbidity in patients with COVID-19. 3 COVID-19 also lead to many cardiovascular diseases, such as cardiac arrhythmias, myocardial infarction, cardiomyopathy, shock, and cardiac arrest. 4 Cardiac injury is defined as the level of serum troponin with at least one value was above the 99th percentile upper reference according to latest guideline. 5 Recently, a body of the literatures 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] shown that acute cardiac injury occurs in patients with However, the reported prevalence of cardiac injury on COVID-19 varies from one to another. In a cohort of 138 hospitalized patients with COVID-19 from Wuhan, 4 cardiac injury was reported in 11.2% of hospitalized patients and 22% of intensive care unit (ICU) patients.

Another study from New York City has reported the existence of cardiac injury in 36% of patients hospitalized with COVID-19. 14 The exact prevalence of cardiac injury in hospitalized patients with COVID-19 is still not clear.

Moreover, accumulating evidence 3,4,6-24 supports the notion that acute cardiac injury leads to other poor outcomes patients with cardiac injury had a significantly higher mortality risk than those without cardiac injury. We therefore conducted a systematic review and meta-analysis to investigate the reported prevalence and impact of cardiac injury on COVID-19.

This meta-analysis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for studies that evaluate healthcare interventions (http://www. prisma-statement.org). 25 This study has been registered with PROS-PERO (International prospective register of systematic reviews)registration number-CRD 42018090474. Severe COVID-19 patients is defined as patients with COVID-19 who are admitted to an ICU patients, while the non-severe COVID-19 patients is defined as hospital patients with COVID-19 who are not admitted to an ICU. Ethical approval is not applicable for this study.

We conducted computerized searches of the Cochrane Library, PubMed, MedRxiv (https://www.medrxiv.org/), and Embase databases from December 2019 to July 2020 (Table S1 in Supplemental material). To identify studies involving relevant COVID-19, we performed the search using the following terms: 2019-novel coronavirus, SARS-CoV-2, COVID-19, and 2019-nCoV. To identify studies involving outcomes, we performed the search using the following terms: cardiac injury, myocardial injury, and cardiac troponin. The definition of cardiac injury was those adopted by the original studies (Table S2 in Supplemental material).

Two groups of keywords were combined using the Boolean operator "and." No language restrictions were applied for the literature search. We also reviewed reference lists, relevant journals, and conference abstracts to identify relevant studies. Additionally, we searched ClinicalTrial.gov (https://www.clinicaltrials.gov/) to obtain information on studies that were terminated before being published.

Studies were considered eligible if they (1) were cohort or nested case-control studies; (2) reported the prevalence of cardiac injury;

(3) reported the association between cardiac injury and outcomes (e.g. all-cause death) in this illness. Certain publication types (e.g., reviews, editorials, and animal studies) or studies with insufficient data were excluded from this analysis.

Two researchers (Linghua Fu and Yuhao Su) extracted the basic characteristics, including the first author, publication year, geographical location, study type, participants (sex, age, and sample size), and duration of follow-up. For multiple reports using the same data, we included the articles with the longest follow-up or the largest numbers of participants. The quality of all prevalence studies was independently assessed by the Joanna Briggs Institute critical appraisal checklist. In addition, we assessing the quality of included studies involved with the impact of cardiac injury by Newcastle-Ottawa quality scale (NOS), which entailed evaluations of the selection of cohorts, the comparability of cohorts, and the assessment of outcome. In this meta-analysis, we defined studies with an NOS of ≥6 stars as moderate to high-quality studies; studies which lower scores were defined as low-quality studies. 26, 27 Two researchers discussed the topics during several face-to-face and web-based meetings. ware. The exact binomial (Clopper-Pearson) method was used to calculate 95% confidence intervals (CIs). Estimates were normalized using the Freeman-Tukey double arcsine transformation. We selected a random effects model to evaluate summary prevalence. The effect measurement estimate of mortality risk chosen was the odds ratio (ORs) in our study. Risk ratio and hazard ratio in other studies were considered to be OR, as OR was shown to be a more effective measure. 28 If not available, the ORs were calculated by events and total numbers of patients in two groups. The natural logarithm of the OR (log [OR]) and its standard error (SElog [OR]) were calculated and then pooled using statistical software. Cochran's chi-square test and I 2 statistic were used to evaluate the heterogeneity among the included studies. I 2 values of 25%, 50%, and 75% were considered to represent low, moderate, and high heterogeneity, respectively. 29, 30 The statistical significance threshold was set at p < .05.

We screened 811 potentially relevant articles in the Cochrane Library (n = 19), PubMed (n = 393), MedRxiv (n = 286), and Embase (n = 113) databases ( Figure S1 in Supplemental Material). We excluded 91 studies after screening the titles and abstracts, and the full texts of the remaining 720 studies were reviewed. After a quick screening of the full-text articles, 30 records were received full-test review, and 9 excluded for the following reasons: (1) seven studies did not have relevant results, and (2) two studies 31, 32 were based on same population. Finally, 21 studies 3,4,6-24 were included in the present metaanalysis.

The study characteristics were shown in Table 1 studies, and three 10, 12, 15 were prospective observational (cohort) studies. 3.3 | The prevalence of cardiac injury in hospitalized patients with COVID-19

As presented in Figure 1 , a total of 20 studies 3,4,6-23 comprising 6130

hospitalized patients with COVID-19 were included in the meta-analysis, resulting a pooled cardiac injury prevalence of 22% (95% CI: 16%

to 28%), with a high heterogeneity (I 2 = 97.0%).

There were 11 studies reported the incidence of cardiac injury in severe COVID-19 and non-severe COVID-19 patients, with 1781 or 914 subjects, respectively. The overall incidence of cardiac injury ranges from 10.2% to 69.2% and 1.0% to 9.0% in severe and non-severe COVID-19 patients, respectively. The pooled prevalence of cardiac injury was 42.0% (95% CI: 29% to 54%, I 2 = 97%) among severe patients with COVID-19 and 6% (95% CI: 3% to 9%, I 2 = 77%) among non-severe patients with COVID-19 with a high heterogeneity (Figure 2 ).

In further subgroup analysis defined by age, there was a significant increased incidence of cardiac injury in older COVID-19 patients (≥60 years) (ES: 15%, 95% CI: 10% to 21%, I 2 = 92%) compared with young COVID-19 patients (ES: 30%, 95% CI: 25% to 36%, I 2 = 92%) (< 60 years) ( Figure S2 ). There was no significant difference in cardiac injury in patients with COVID-19 among the region subgroup (China and USA) ( Figure S3 ).

There were 10 publications 3,4,12,13,19-24 reported the association between cardiac injury and death. As shown in Figure 3, 

There were two studies 4, 7, 12, 15 reported the association between cardiac injury and death in patients with severe COVID-19. None of F I G U R E 2 Meta-analysis for the proportion of cardiac injury in patients hospitalized with severe and non-severe COVID-19

included studies reported the adjusted results, thus, forced us to perform a univariate analysis. As presented in Figure 4 , cardiac injury is 

Some limitations may influence the validity of this meta-analysis. First, all the included studies were observational studies and some studies did not adjust for the clinical confounding in the outcome of death and these biases might influence on our results. For example, ACEI/ ARB, as we describe previously, was showed be associated with decreased risk of death in COVID-19 42 . However, although with number changes, the positive association between cardiac injury and death was still persisted when excluding the unadjusted studies, which showed the robustness of our conclusion. Second, the definition of the cardiac injury differed across the included trials and potentially affected the findings. Third, the majority of studies are from China, the studies involved with the prevalence and impact of cardiac injury on COVID-19 is needing to confirm this conclusion. Fourth, high heterogeneity existed across studies in some comparisons, limiting the interpreting on the results, however, we attempted to account for this by using a random effect model to make our results more conservable. The precise number for the type of cardiac injury is lacking, therefore, we cannot evaluate the association between type of cardiac involvement and adverse prognosis. Finally, lots of studies did not provide the adjusted results, thus, further studies with welldesigned are needed to confirm our results.

This was the first meta-analysis exploring the prevalence and impact of cardiac injury on COVID-19. Cardiac injury is common in hospitalized patients and advanced age and severe COVID-19 patients prone to experience more risk of cardiac injury. Furthermore, cardiac injury is associated with increased risk of all-cause mortality.

Severe Covid-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Fourth universal definition of myocardial infarction

Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019

Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study

Analysis of 92 deceased patients with COVID-19

Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan

Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China

The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Association of Cardiac Injury with Mortality in hospitalized patients with COVID-19 in Wuhan, China

Cardiac troponin I is an independent predictor for mortality in hospitalized patients with COVID-19

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

The relationship between vitamin D and risk of atrial fibrillation: a dose-response analysis of observational studies

The obesity paradox for outcomes in atrial fibrillation: evidence from an exposure-effect analysis of prospective studies

Questionable utility of the relative risk in clinical research: a call for change to practice

The obesity paradox for outcomes in atrial fibrillation: Evidence from an exposure-effect analysis of prospective studies

Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

COVID-19 and cardiovascular disease

COVID-19 and the cardiovascular system

Sex differences in the relationships between BMI, WHR and incidence of cardiovascular disease: a population-based cohort study

Sex difference and smoking predisposition in patients with COVID-19

Covid-19: low dose steroid cuts death in ventilated patients by one third, trial finds

Remdesivir for the treatment of Covid-19 -final report

High-sensitivity cardiac troponin can be an ally in the fight against COVID-19

ST-segment elevation in patients with Covid-19 -a case series

Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clinical Cardiology

SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article. How to cite this article

All authors have no conflicts of interest that might be relevant to the contents of this manuscript.

https://orcid.org/0000-0002-5570-289XKui Hong https://orcid.org/0000-0002-0875-0557